Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Overview of attention for article published in Journal of Clinical Oncology, March 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

news: 3 news outlets

twitter: 12 X users

Readers on

mendeley: 56 Mendeley

So far, Altmetric has seen 12 X posts from 12 X users, with an upper bound of 20,825 followers.

https://t.co/IKng4PJZtr

今日の抄読会📖 プラチナ感受性再発卵巣癌に対して、プラチナベースの化学療法（TC, PLD-C，GC） vs オラパリブ（600㎎/日） vs オラパリブ（400㎎/日）＋セジラニブ（30㎎/日）の第Ⅲ相試験 https://t.co/krvmgQJWGy

RT @cancer_evolve: DRUG TARGETS [1]: two recent studies failed to show benefit of PARP inhibition in unselected patients with ovarian or bl…

RT @generoom: Unsurprisingly, targeted therapy doesn't work if you don't target it. #parpinhibitors #genomics #diagnostics

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.